Two treatments that do not do the same thing

ChondroFiller and hyaluronic acid are not two versions of the same treatment. One is a structural scaffold placed directly inside a damaged area of cartilage; the other is a lubricating fluid supplement added to the joint space. The difference is categorical — comparable to filling a pothole versus repaving the whole road surface — not simply a question of how long the effect lasts.

Most patients who arrive asking 'which is better?' are, on the basis of their diagnosis, already candidates for only one of these options. A discrete, MRI-confirmed focal cartilage defect and diffuse osteoarthritis spread across a joint surface are not the same condition, and they do not respond to the same treatment. Choosing between ChondroFiller and hyaluronic acid is therefore not a matter of preference or tolerability — it follows from what the joint actually has wrong with it. The sections below explain the mechanism and indication of each so the distinction becomes clear.

How ChondroFiller fills a cartilage defect

Placed under ultrasound guidance in a single outpatient appointment, ChondroFiller is a CE-marked, injectable Type I collagen gel specifically designed for the kind of discrete, deep focal defect described in the previous section — the pothole, not the worn road surface.

Once the gel is delivered into the defect, body temperature (around 30–33°C) triggers it to set within approximately 3–5 minutes, forming a dimensionally stable 3D hydrogel that physically occupies and supports the lesion without the need for surgical fixation, fibrin glue, or a biopsy. The scaffold is acellular — it contains no donor cells — which means its immediate role is structural: creating a matrix that the patient's own progenitor cells can migrate into from the surrounding subchondral bone and synovium.

That cell migration is not simply a theoretical expectation. A 2025 ex vivo study measured a 2.4-fold increase in DNA content within the collagen scaffold by day 14, providing direct evidence of active cell ingrowth in the early weeks after placement.

Over the following 12–24 months, the collagen matrix is gradually broken down by the body and replaced by the repair tissue those recruited cells have been producing. The aim is to support the body's own repair process from within the defect rather than deliver a temporary chemical effect — which is why a single treatment course, rather than repeated injections, is the intended pathway.

How hyaluronic acid lubricates the joint

Hyaluronic acid (HA) viscosupplementation works on a fundamentally different principle. Rather than being placed into a discrete lesion, HA is injected into the general joint space, where it supplements the synovial fluid that has become depleted or degraded in osteoarthritic joints. By restoring viscosity, it reduces the mechanical friction that healthy synovial fluid normally manages — which is why its primary indication is mild-to-moderate diffuse osteoarthritis (Kellgren-Lawrence grades I–III), where the problem is spread across the joint surface rather than concentrated in one structural gap.

The mechanism extends slightly beyond simple lubrication. HA molecules can bind to CD44 receptors on chondrocytes and synovial cells, stimulating modest matrix production and anti-inflammatory effects — a process sometimes called 'viscoinduction'. These biological effects are real, but they do not amount to structural cartilage repair: HA does not fill, bond to, or rebuild a discrete cartilage lesion.

In terms of durability, published data suggest clinical benefit typically persists for around 6–12 months, after which a repeat course is usually needed to maintain relief. Evidence also indicates HA performs better than corticosteroids over the medium-to-long term, though not necessarily in the first four weeks. How well any individual responds may depend on factors such as body weight and the severity and distribution of their OA.

The diagnosis that decides which treatment applies

The distinction between focal defect and diffuse osteoarthritis is not merely academic — it is the clinical gate through which every treatment decision must pass, and MRI is the tool that opens or closes it.

X-ray and clinical examination can suggest the severity of joint degeneration, but they cannot reliably distinguish a contained focal lesion from widespread cartilage loss. An MRI can: it characterises the depth and geometry of a discrete defect, confirms whether the subchondral bone plate is intact, and — crucially — shows whether the damage is localised or distributed broadly across the joint surface. A Grade III or IV focal lesion identified on MRI is the signal that a scaffold approach may be appropriate. Diffuse degenerative change across multiple compartments points in a different direction entirely, towards viscosupplementation or other palliative strategies.

This matters because no amount of clinical preference or symptom severity changes what the underlying anatomy requires. A patient whose MRI confirms widespread cartilage thinning is not a candidate for ChondroFiller regardless of how long they want their relief to last. Equally, HA injected into the general joint space cannot reach into, stabilise, or fill a deep focal cavity.

MRI is what turns a comparison like this one from theoretical to actionable for any individual patient — it is the step that makes the right treatment choice visible.

What the evidence shows — and where gaps remain

Published cohort series indicate that a meaningful proportion of patients treated with ChondroFiller sustain symptom relief over several years from a single injection course — with approximately 80% rating outcomes as good or very good in reported data. Those figures derive from cohort studies rather than randomised controlled trials, and no head-to-head RCT directly comparing ChondroFiller with HA in matched patients currently exists. Any direct comparison between the two treatments therefore remains inferential rather than trial-derived.

The evidence base for HA is larger in volume but more contested in interpretation. A 2026 Australian prescriber review, drawing on large RCT meta-analyses, found that intra-articular HA provided no important clinical benefit for knee osteoarthritis and carried meaningful risks — including septic arthritis and severe inflammatory reactions — leading to a conditional recommendation against routine use. The EUROVISCO 2024 consensus reached a more permissive conclusion: in well-phenotyped patients (non-obese, early-to-moderate OA at Kellgren-Lawrence grades I–III, no active inflammatory flare), it found strong evidence in favour of HA. These two positions have not been reconciled, and the evidence-to-practice gap remains real.

What can be said plainly is that the two treatments sit at different points on the research maturity curve and serve fundamentally different clinical purposes. Where they appear to overlap in the literature — both targeting knee pain, both delivered as outpatient injections — the underlying patient populations rarely overlap in the clinic.

Working out which option suits your situation

Knowing which treatment category applies is one piece of the picture; establishing whether a specific patient is a suitable candidate for that treatment is another. Neither ChondroFiller nor HA suits every patient who meets the basic diagnostic criterion. Defect size, the condition of the surrounding cartilage and subchondral bone, overall joint health, age, activity level, and symptom duration all factor into the clinical assessment — and a consultant reviewing imaging is better placed to weigh those variables than any symptom checklist.

For patients whose MRI has not yet been formally reviewed in the context of injection candidacy, that review is a reasonable first practical step. A structured assessment that takes imaging into account — rather than symptom description alone — is the appropriate way to establish whether a scaffold approach, viscosupplementation, or a different pathway altogether is likely to be relevant. That kind of structured review is available via the assessment pathway on amsk.co.uk.

The clearest take-away from this comparison is also the most practical one: treatment choice follows diagnosis, not symptom severity. A long-standing diffuse ache and a recent sharp-onset localised pain may feel similar to the person experiencing them, but mean very different things on imaging — and therefore call for very different interventions.

1. [1] Evaluation of effectiveness of hyaluronic acid viscosupplementation in knee OA – narrative review. (2026). https://doi.org/10.12775/qs.2026.53.69889 https://doi.org/10.12775/qs.2026.53.69889
2. [2] Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis: is it effective?. (2026). https://doi.org/10.18773/austprescr.2026.005 https://doi.org/10.18773/austprescr.2026.005